Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org
SOURCE Wall St. Equities
NEW YORK, April 16, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ABBV, BSPM, BMY, and LLY which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Drug Manufacturers space, which develops and sells medicines and vaccines for a wide range of medical uses. Most drug manufacturers are structured as corporations, and many of these companies offer slightly higher-than-average dividend yields. Under review are the four major industry players, namely: AbbVie Inc. (NYSE: ABBV), Biostar Pharmaceuticals Inc. (NASDAQ: BSPM), Bristol-Myers Squibb Co. (NYSE: BMY), and Eli Lilly and Co. (NYSE: LLY). All you have to do is sign up today for this free limited time offer by clicking the link below.
North Chicago, Illinois-based AbbVie Inc.'s shares recorded a trading volume of 4.62 million shares last Friday. The stock finished the trading session 0.31% lower at $91.83. The Company's shares have surged 42.66% over the past year. The stock is trading below its 200-day moving average by 1.00%. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 34.17.
On April 06th, 2018, AbbVie announced that it will report its Q1 2018 financial results on April 26th, 2018, before the market opens. The Company will host a live webcast of the earnings conference call at 9:00 a.m. ET that same day. The webcast will be accessible on the Company's Investor Relations website. Get the full research report on ABBV for free by clicking below at: www.wallstequities.com/registration/?symbol=ABBV
On Friday, Xianyang, China headquartered Biostar Pharmaceuticals Inc.'s stock ended the session 2.25% lower at $3.04. A total volume of 18,805 shares was traded. The Company's shares have surged 55.09% over the previous three months and 33.92% over the past year. The stock is trading 42.94% above its 200-day moving average. Moreover, shares of Biostar Pharma, which develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in China, have an RSI of 41.32. The free technical report on BSPM can be accessed at: www.wallstequities.com/registration/?symbol=BSPM
New York headquartered Bristol-Myers Squibb Co.'s stock ended the day 0.32% lower at $58.65. A total volume of 10.67 million shares was traded, which was above their three months average volume of 7.93 million shares. The Company's shares have gained 10.68% over the past year. The stock is trading 4.77% below its 200-day moving average. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 32.29.
On April 02nd, 2018, Bristol-Myers Squibb (BMY) announced that it will hold an investor event on April 16th, 2018, at 6:00 p.m. EDT to discuss data presented at the Annual Meeting of the American Association for Cancer Research in Chicago. BMY executives will provide an overview of data presented from the Company's oncology portfolio, and address questions from investors and analysts.
On April 12th, 2018, research firm Citigroup reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $78 a share to $70 a share. Sign up for free on Wall St. Equities and claim the latest report on BMY at: www.wallstequities.com/registration/?symbol=BMY
Shares in Indianapolis, Indiana headquartered Eli Lilly and Co. recorded a trading volume of 2.65 million shares. The stock ended Friday's session 0.54% higher at $79.72. The Company's shares have gained 1.57% in the last month. The stock is trading above its 50-day moving average by 2.30%. Furthermore, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 57.82.
On April 04th, 2018, Eli Lilly announced that it will report its financial results for Q1 2018 on April 24th, 2018. The Company will conduct a conference call 9:00 a.m. ET that same day to further detail its financial performance. A link to the live webcast of the conference call will be posted on the Company's website.
On April 13th, 2018, research firm BMO Capital Markets upgraded the Company's stock rating from 'Underperform' to 'Market Perform' while revising its previous target price from $74 a share to $79 a share. See the free research coverage on LLY at: www.wallstequities.com/registration/?symbol=LLY
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2017 PR Newswire. All Rights Reserved.